We seek a healthier tomorrow

Ardy Arianpour, CEO & Co-Founder of Seqster, is a visionary genomics executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics and SVP of Ambry Genetics, which sold to Konica Minolta for $1B in 2017. He is one of the main architects in launching the first commercial clinical exome sequencing test in 2011, establishing the value of next-gen sequencing in the clinic. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from University of California Irvine and an MBA from Marshall Goldsmith School of Management.

Xiang (Sean) Li, CTO & Co-Founder, is a technology executive experienced at building and leading technical teams with expertise in clinical bioinformatics, data science, and software engineering. Dr. Li has a strong track record of delivering results by developing big-picture product strategies and following up with methodical execution. Previously, he was the Vice President of Clinical Bioinformatics at Pathway Genomics. Prior to that, he was the Director of Bioinformatics Development at Ambry Genetics where he led the implementation of the first commercial clinical exome sequencing test in 2011 and hereditary cancer panels based on next-gen sequencing. Dr. Li received his doctoral degrees in Bioinformatics from the University of Illinois, Chicago.

Dana Hosseini, CIO & Co-Founder, is a serial entrepreneur who has managed and co-founded a number of genomics-based companies including ProdermIQ, Iceland Genomics, and DiThera. Mr. Hosseini’s skills in international medical device and diagnostics sales and marketing were developed at Abbott Laboratories, OrthoClinical Diagnostics (Johnson & Johnson), and Sequenom where he held executive and management positions in business development, sales, and marketing functions. He has 25+ years of extensive experience working with big biotech and pharmaceutical companies globally. Dana received both his BS in Biochemistry and Genetics and MBA from the University of British Columbia.

Jon Vance, CFO, has over 15 years of investment banking experience and founded MedDx in 2011 to better serve the capital and strategy objectives of growth-stage diagnostics companies. Prior to founding MedDx, Jon led Avondale Partners’ West Coast Healthcare investment banking efforts and advised public and private in vitro diagnostics and lab companies. While at Avondale, Jon completed over $1.5B worth of transactions. Jon began his career in the corporate finance departments of Coopers & Lybrand and Ernst & Young, where select clients included Roche Diagnostics, IGEN, and the University of California San Diego Hospital. He is a CFA® charterholder and a Certified Public Accountant. Jon earned bachelor's degrees in both Accounting and Finance from Miami University.